The estimated Net Worth of Peter K. Watler is at least $20.8 Тысяча dollars as of 8 August 2016. Peter Watler owns over 55,621 units of Coherus Biosciences Inc stock worth over $20,776 and over the last 10 years Peter sold CHRS stock worth over $0.
Peter has made over 11 trades of the Coherus Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Peter exercised 55,621 units of CHRS stock worth $122,366 on 8 August 2016.
The largest trade Peter's ever made was exercising 73,741 units of Coherus Biosciences Inc stock on 20 July 2016 worth over $137,896. On average, Peter trades about 23,482 units every 15 days since 2015. As of 8 August 2016 Peter still owns at least 15,621 units of Coherus Biosciences Inc stock.
You can see the complete history of Peter Watler stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle и James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Coherus Biosciences Inc executives and other stock owners filed with the SEC include: